Naila Rabbani (B.Sc. Biological & Medicinal Chemistry, 1998 and PhD Biochemistry, University of Essex, Colchester, U.K.), previously known as Naila Ahmed, is Adjunct Professor, College Medicine, Qatar University, Doha, Qatar and Director, Glocentrica Ltd, based in the UK. She is a biomedical research scientist with over 25 years’ experience in clinical translational research. She is a leading international expert in protein glycation research in which she developed the AGEomics technology and pioneered the application of artificial intelligence (AI) machine learning for the development of diagnostic algorithms with protein glycation biomarkers as features.

In 2014, Rabbani, then faculty member at Warwick Medical School, led protein glycation analysis in the Healthy Aging Through Functional Food (HATFF) clinical trial of glyoxalase 1 inducer, trans-resveratrol and hesperetin, finding that it decreased protein glycation by methylglyoxal and metabolism-linked low-grade inflammation, and corrected insulin resistance in overweight and obese subjects.

In the past decade, Professor Rabbani has made multiple seminal contributions to the causes and consequences of increased methylglyoxal concentration, dicarbonyl stress, and related protein glycation – including its origin in insulin resistance, beta-cell glucotoxicity and diabetes, consequences for increased metabolic stress and inflammation through activation of the unfolded protein response, and methylglyoxal protein glycation adducts as diagnostic indicators of glycemic disease.She has 301 publications (153 peer reviewed papers and 168 conference abstracts and papers) with over 17,000 citations; h-index 71 (Google Scholar). By h-index, she is in the top 3% of scientists globally (AD Scientific Index).